Cytarabine

• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended
  2024-514473-21-00 Phase III 3 countries Klinikum Der Landeshauptstadt Stuttgart gKAöR
• A Study of the Efficacy and Safety of Galinpepimut-S (GPS) for the Treatment of Acute Myeloid Leukemia Compared to Investigator's Choice of … Ended
  2024-516405-23-00 Phase III 5 countries Sellas Life Sciences Group Inc.
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended
  2024-516868-28-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended
  2023-504805-35-00 Phase I/II 10 countries Genmab A/S
• Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended
  2023-507062-34-00 Phase I (FiH) 5 countries Novartis Pharma AG
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended
  2023-503670-21-00 Phase III 2 countries Universitaetsklinikum Ulm AöR
• Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended
  2024-515375-35-00 Phase II 2 countries GWT-Tud GmbH
• HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea… Ended
  2023-509019-97-00 Phase I/II 1 country Karolinska University Hospital
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended
  2023-509834-20-00 Phase II 6 countries Novartis Pharma AG
• Study to determine safety, efficacy and tolerability of Venetoclax in combination with Fludarabine, Citarabine and Idarubicin to achieve "th… Ended
  2023-510517-26-00 Phase I/II 1 country Fondazione Gimema Franco Mandelli Onlus
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended
  2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
• Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Fin… Ended
  2024-516112-21-00 Phase III 2 countries The University Of Birmingham
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended
  2024-515499-12-00 Phase III 12 countries Universita Degli Studi Di Milano Bicocca
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended
  2023-505509-18-00 Phase III 7 countries Universitaetsklinikum Muenster AöR
• HOVON 127 BL / SAKK 37/16: Phase III study comparing 2 treatments (R-CODOX-M/R-IVAC versus DA-EPOCH-R) in patients with Burkitt lymphoma Ended
  2023-503423-25-00 Phase III 2 countries Haemato Oncology Foundation For Adults Netherlands
• A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted
  2023-506136-32-00 Phase I/II 7 countries Amgen Inc.
• A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabi… Ended
  2024-516388-10-00 Phase I/II 2 countries Moleculin Biotech Inc.
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid… Ended
  2024-512469-15-00 Phase I/II 4 countries Astellas Pharma Global Development Inc.
• Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended
  2024-514018-12-00 Phase I/II 1 country Technische Universitaet Dresden
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 Phase III 7 countries Novartis Pharma AG
• Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended
  2024-511533-35-00 Phase II 1 country Fondazione Italiana Linfomi Ets
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 Phase II 4 countries Kite Pharma Inc.

Showing 49–72 of 75 trials